Clinical Trial Update: A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating almonertinib with concurrent radiotherapy in locally advanced EGFR-mutant non-small cell lung cancer (Stage III NSCLC). Status details …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)

Snippet

Sponsor: First People's Hospital of Hangzhou | Conditions: Non Small Cell Lung Cancer, Stage III NSCLC | Phase 2 | Status: UNKNOWN